Abiraterone (Zytiga): Mechanism of Zytiga
Steroid/androgen synthesis pathway and the sites of inhibition of... | Download Scientific Diagram
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy - Njar - Translational Cancer Research
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer | Scientific Reports
CYP17A1 - an overview | ScienceDirect Topics
P450 Signaling | CYP450
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Abiraterone Acetate | ≥99%(HPLC) | Selleck | P450 (e.g. CYP17) inhibitor
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
CYP17A1 - an overview | ScienceDirect Topics
Steroid synthesis pathway and aromatization. Abiraterone is a novel... | Download Scientific Diagram
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer | Oncology
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
CYP17A1 inhibitor - Wikipedia
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1 | Drug Metabolism & Disposition
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases - ScienceDirect
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential | Semantic Scholar
